Scottish HTA Finally OKs Roche’s Perjeta For Metastatic Breast Cancer
Executive Summary
The Scottish health technology assessment body, the SMC, has recommended a number of products for funding under NHS Scotland: Roche’s breast cancer drug Perjeta, Pfizer’s Xeljanz for psoriatic arthritis, and two antidiabetics, MSD’s Steglatro (ertugliflozin) and Novo Nordisk’s Ozempic (semaglutide).
You may also be interested in...
Bruised Roche Wins Another UK Perjeta Round With Price Cut
In the latest round of what appears to have been a bruising set of price negotiations for Roche, the UK’s cost effectiveness agency NICE has recommended Perjeta in another breast cancer setting.
NICE Reverses View On Perjeta In Breast Cancer After Roche's Price Cut
The UK's HTA NICE says it is now backing Roche's Perjeta (pertuzumab) to treat a certain form of breast cancer on the publicly funded NHS after Roche offered a price discount.
WHO Launches Twin-Track Procedure To Speed Access To Health Products
A procedure used to accelerate the approval of COVID-19 products during the pandemic is to be applied to all medicines using “synchronized and parallel, but otherwise entirely independent, processes,” the World Health Organization says.